NCT00141830View on ClinicalTrials.gov

Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL

Enrollment

159

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

October 19, 2006

Study Completion Date

October 19, 2006

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Methotrexate plus ERB-041 for 12 weeks

DRUG

Placebo for 12 weeks

Trial Locations (35)

1027

Budapest

5600

Békéscsaba

8200

Veszprém

16132

Genova

19002

Castilla La Mancha

21702

Frederick

25100

Brescia

27100

Pavia

28040

Madrid

28210

Charlotte

33773

Largo

34239

Sarasota

34684

Palm Harbor

41013

Andalucia

44620

Jalisco

46017

Comunidad Valenciana

53100

Siena

54601

La Crosse

66160

Kansas City

75231

Dallas

78217

San Antonio

78705

Austin

83702

Boise

87131

Albuquerque

99204

Spokane

16635-0909

Duncansville

V2A 3G8

Penticton

L3Y 3R7

Newmarket

M5T 2S8

Toronto

H2L 1S6

Montreal

G8Z 1Y2

Trois-Rivières

S7K 0H6

Saskatoon

G1W 4R4

Québec

00100

Roma

06700

Delegacion Cuahutemoc

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00141830 - Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter